Finding new tenants for former drug development sites isn’t always easy. But a new, thriving industry has materialized to do just that.

With three recent FDA approvals, and a number of Phase 3 trials ongoing, the drugs are seeing a surge in interest.

An exploration of the genetics of earlobe attachment is just the latest collaborative research project to come out of the personal genetic testing company.

The pharma giant is purchasing the San Francisco–based cancer drugmaker to boost its oncology portfolio.

Experiments conducted at the New York University School of Medicine violated several research standards, according to US Food and Drug Administration investigators.

The acquisition-hungry pharmaceutical firm is purchasing the California-based eczema gel maker.

A move by the US federal government to close tax loopholes that encourage “tax inversions” likely spooked the companies out of the multibillion dollar deal.

The two drugmakers will join forces in a $160 billion deal—if it’s given the regulatory green light.

The pharmaceutical giant is purchasing the injectable drugmaker for about $15 billion.